12th July 2021

Pharmanovia Announces CEO Transition Plan

  • Amit Patel is retiring as CEO, will transition to the Advisory Committee
  • James Burt will take over the responsibilities as CEO, effective October 1st, 2021

Basildon (UK), 3 June, 2021 – Pharmanovia announced as part of the leadership transition process, that Dr Amit Patel will retire as Chief Executive Officer and James Burt has been appointed and will start as new CEO of Pharmanovia – the original medicines specialist globally, effective October 1st, 2021. The transition has been planned well ahead of time in close cooperation between Dr Patel and the Advisory Committee and is designed to ensure a smooth transition of responsibilities. Dr Patel will continue to support the company going forward as a member of the Advisory Committee.

“On the back of our strong growth track record to a truly global specialty pharma company, we have developed and are executing a transformation plan that will serve as a foundation for continued growth and expansion of our leading position as the original medicines specialist globally. I believe now is the logical time for me to begin the process of turning the reins over to Pharmanovia’s next CEO”, said Dr Amit Patel.

Dr Jörg-Thomas Dierks, Chairman of the Advisory Committee comments on behalf of the Advisory Committee: “We are very grateful for all the outstanding work done by Amit over the last seven years, from the inception of the company and growing it to a global business and preferred partner for innovator pharma companies. Followed by a period of successful ownership change and partnership with Triton and a series of strategic and significant acquisitions, as well as in assembling a first-class executive team with deep pharma industry expertise and exceptional drive and commitment. We would like to thank Amit for his outstanding commitment, strategic leadership and entrepreneurial drive over the years and of course for the strong and trustful partnership to date. We are honoured and very grateful that Amit will continue to support the company and its continuing growth journey as a member of the Advisory Committee.”

James Burt is a strategic thinker who has significant relevant leadership experience and is currently Executive Vice President EMENA at Accord Healthcare overseeing both branded and generic pharmaceutical activities across approximately 65 countries. Previous to that he served as Vice President Hospital Business at Actavis, where here he was responsible for the strategic direction of the company’s secondary care focused activities worldwide. He holds a PhD in Chemical Engineering from the University of Birmingham which was particularly focused on biopharmaceutical manufacturing.

Dr Jörg-Thomas Dierks, Chairman of the Advisory Committee said on behalf of the Advisory Committee: “We are confident that James Burt will accelerate Pharmanovia’s profitable growth through the progression and evolution of our product portfolio, further strategic acquisitions as well as digital solutions. James combines exceptionally strong pharmaceutical and operational expertise with strong strategic and commercial thinking.”


About Pharmanovia – The original medicines specialist globally

Our purpose is to progress iconic medicines for the benefit of patient health globally.

We provide iconic, tried and trusted medicines in the strategic therapeutic areas of Cardiovascular, Women’s Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology.

We own some of the world’s most recognisable brands, including Bonviva®, Inderal®, Kytril®,  Naprosyn®, Valium®, Zestril® and more.

We operate a portfolio of 20+ brands in 140+ markets with over 200 employees, and we grow through development, licensing and acquisition.